A sponsor was in a tight race to market when it initiated a phase III, two-protocol clinical trial designed to evaluate the efficacy and safety of its inhaler-delivered drug in pediatric patients with persistent asthma.
Breathe easier with Acurian.
Acurian has developed multi-tactic campaigns to support: asthma, bronchiectasis, COPD, emphysema, grass pollen-induced rhinoconjunctivitis, idiopathic pulmonary fibrosis, pediatric common cold, pulmonary arterial hypertension, and upper respiratory infection.
Acurian is the leader in the patient recruitment and retention industry.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.